Platelets, inflammation and anti-inflammatory drugs in ACS and CAD

Karsten Schrör; Kurt Huber

doi:10.1160/TH15-08-0632

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2015; 114(03): 446-448
DOI: 10.1160/TH15-08-0632

Theme Issue Editorial

Schattauer GmbH

Platelets, inflammation and anti-inflammatory drugs in ACS and CAD

Authors

Karsten Schrör

¹UniversitätsKlinikum Düsseldorf, Institut für Pharmakologie und Klinische Pharmakologie, Düsseldorf, Germany
Kurt Huber

²3rd Department of Internal Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria

Abstract

Full Text

References

References
1 Weber AA. et al. Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors. Thromb Res 2002; 106: 25-29.
2 Weber AA. et al. No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors. Pharmacogenetics 2002; 12: 581-583.
3 Serebruany VL. et al. Uniform platelet activation exists before coronary stent implantation despite aspirin therapy. Am Heart J 2001; 142: 611-616.
4 Lievens D, von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost 2011; 106: 827-838.
5 Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105 (Suppl. 01) S13-33.
6 Massberg S. et al. Role of platelets in the patho-physiology of acute coronary syndrome. Semin Vasc Med 2003; 03: 147-162.
7 Weyrich AS. et al. The evolving role of platelets in inflammation. J Thromb Haemost 2003; 01: 1897-1905.
8 Thomas M, Storey R. The role of platelets in inflammation. Thromb Haemost 2015; 114: 449-458.
9 Freynhofer M, Huber K. Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers vs. platelet function testing. Thromb Haemost 2015; 114: 459-468.
10 Passacquale G, Ferro A. Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation. Br J Clin Pharmacol 2011; 72: 604-618.
11 von Brühl ML. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819-835.
12 Larsen SB. et al. Platelet turnover in stable coronary artery disease – influence of thrombopoietin and low-grade inflammation. PLoS One 2014; 09: e85566.
13 Schrör K. Why we should not skip aspirin. Haemostaseologie 2015; in press.
14 Hohlfeld T, Schrör K. Antiinflammatory effects of aspirin in ACS: relevant to its cardiocoronary actions?. Thromb Haemost 2015; 114: 469-477.
15 Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost 2010; 103: 71-82.
16 Undas A. et al. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 2007; 109: 2285-2292.
17 Wolzt M. et al. Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber. Thromb Res 2013; 132: 240-247.
18 Gurbel PA. et al. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb Res 2007; 119: 563-570.
19 Undas A. et al. Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin. Thromb Haemost 2007; 97: 1056-1058.
20 Morris T. et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol 2009; 183: 2089-2096.
21 Schrottmaier W. et al. Aspirin and P2Y₁₂ inhibitors in platelet-mediated activation of neutrophils and monocytes. Thromb Haemost 2015; 114: 478-489.
22 Pettersen AA, Seljeflot I, Abdelnoor M. et al. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 2004; 38: 353-356.
23 Thomas M, Storey R. Effect of P2Y₁₂ inhibitors on inflammation and immunity. Thromb Haemost 2015; 114: 490-497.
24 Totani L. et al. Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. Thromb Haemost 2012; 107: 1130-1140.
25 Braun OO. et al. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thromb Haemost 2008; 100: 626-633.
26 Müller K. et al. Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD. Thromb Haemost 2015; 114: 498-518.
27 Larsen SB. et al. The influence of low-grade inflammation on platelets in patients with stable coronary artery disease. Thromb Haemost 2015; 114: 519-529.
28 Husted S. et al. Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol 2010; 33: 206-212.